Fosun Pharma reports growth, advances pipeline, plans dividend

Shanghai Fosun Pharmaceutical (Group) Co (HKEX: 2196) announced its audited consolidated financial results for the year ended December 31, 2024, reporting a revenue of RMB40.91 billion. Profit for the year attributable to owners of the parent company increased to RMB2.77 billion, a 15.46% rise year-over-year. Basic and diluted earnings per share both reached RMB1.04. The company plans to distribute a cash dividend of RMB0.32 per share, pending shareholder approval.